349 related articles for article (PubMed ID: 24849361)
1. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
Boehm-Cagan A; Michaelson DM
J Neurosci; 2014 May; 34(21):7293-301. PubMed ID: 24849361
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.
Zhao J; Fu Y; Liu CC; Shinohara M; Nielsen HM; Dong Q; Kanekiyo T; Bu G
J Biol Chem; 2014 Apr; 289(16):11282-11292. PubMed ID: 24599963
[TBL] [Abstract][Full Text] [Related]
4. ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.
Boehm-Cagan A; Bar R; Liraz O; Bielicki JK; Johansson JO; Michaelson DM
J Alzheimers Dis; 2016 Oct; 54(3):1219-1233. PubMed ID: 27567858
[TBL] [Abstract][Full Text] [Related]
5. Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice.
Carter AY; Letronne F; Fitz NF; Mounier A; Wolfe CM; Nam KN; Reeves VL; Kamboh H; Lefterov I; Koldamova R
PLoS One; 2017; 12(2):e0172161. PubMed ID: 28241068
[TBL] [Abstract][Full Text] [Related]
6. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.
Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R
J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429
[TBL] [Abstract][Full Text] [Related]
7. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Corona AW; Kodoma N; Casali BT; Landreth GE
J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
[TBL] [Abstract][Full Text] [Related]
8. Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.
Boehm-Cagan A; Bar R; Harats D; Shaish A; Levkovitz H; Bielicki JK; Johansson JO; Michaelson DM
PLoS One; 2016; 11(11):e0166195. PubMed ID: 27824936
[TBL] [Abstract][Full Text] [Related]
9. ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.
Rawat V; Wang S; Sima J; Bar R; Liraz O; Gundimeda U; Parekh T; Chan J; Johansson JO; Tang C; Chui HC; Harrington MG; Michaelson DM; Yassine HN
J Neurosci; 2019 Nov; 39(48):9611-9622. PubMed ID: 31641056
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.
Kuntz M; Candela P; Saint-Pol J; Lamartinière Y; Boucau MC; Sevin E; Fenart L; Gosselet F
J Alzheimers Dis; 2015; 48(3):849-62. PubMed ID: 26402114
[TBL] [Abstract][Full Text] [Related]
11. Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment.
Salomon-Zimri S; Glat MJ; Barhum Y; Luz I; Boehm-Cagan A; Liraz O; Ben-Zur T; Offen D; Michaelson DM
J Alzheimers Dis; 2016 Jun; 53(4):1443-58. PubMed ID: 27372644
[TBL] [Abstract][Full Text] [Related]
12. Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.
Tachibana M; Shinohara M; Yamazaki Y; Liu CC; Rogers J; Bu G; Kanekiyo T
Exp Neurol; 2016 Mar; 277():1-9. PubMed ID: 26688581
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of ABCA1 and ABCG1 gene expressions in the remodeling mouse hippocampus after entorhinal cortex lesion and liver-X receptor agonist treatment.
Jasmin SB; Pearson V; Lalonde D; Domenger D; Théroux L; Poirier J
Brain Res; 2014 May; 1562():39-51. PubMed ID: 24661912
[TBL] [Abstract][Full Text] [Related]
14. Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity.
Mounier A; Georgiev D; Nam KN; Fitz NF; Castranio EL; Wolfe CM; Cronican AA; Schug J; Lefterov I; Koldamova R
J Neurosci; 2015 Aug; 35(34):11862-76. PubMed ID: 26311769
[TBL] [Abstract][Full Text] [Related]
15. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.
Valencia-Olvera AC; Balu D; Bellur S; McNally T; Saleh Y; Pham D; Ghura S; York J; Johansson JO; LaDu MJ; Tai L
Alzheimers Res Ther; 2023 Dec; 15(1):216. PubMed ID: 38102668
[TBL] [Abstract][Full Text] [Related]
16. ABCA1 haplodeficiency affects the brain transcriptome following traumatic brain injury in mice expressing human APOE isoforms.
Castranio EL; Wolfe CM; Nam KN; Letronne F; Fitz NF; Lefterov I; Koldamova R
Acta Neuropathol Commun; 2018 Jul; 6(1):69. PubMed ID: 30049279
[TBL] [Abstract][Full Text] [Related]
17. Small molecule TBTC as a new selective retinoid X receptor α agonist improves behavioral deficit in Alzheimer's disease model mice.
Sun Y; Fan J; Zhu Z; Guo X; Zhou T; Duan W; Shen X
Eur J Pharmacol; 2015 Sep; 762():202-13. PubMed ID: 26026644
[TBL] [Abstract][Full Text] [Related]
18. RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.
Lefterov I; Schug J; Mounier A; Nam KN; Fitz NF; Koldamova R
Neurobiol Dis; 2015 Oct; 82():132-140. PubMed ID: 26071899
[TBL] [Abstract][Full Text] [Related]
19. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
LaClair KD; Manaye KF; Lee DL; Allard JS; Savonenko AV; Troncoso JC; Wong PC
Mol Neurodegener; 2013 Jun; 8():18. PubMed ID: 23764200
[TBL] [Abstract][Full Text] [Related]
20. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
